Novo Nordisk is making progress toward stabilizing Wegovy supply

Danish pharmaceutical company Novo Nordisk is hard at work with stabilizing the supply of its obesity drug Wegovy, which has been in high demand in the US since its June launch.

By Marketwire og Ulrich Quistgaard, translated by Daniel Pedersen

Published: 25.11.21 at 15:29

Novo Nordisk is currently making progress in securing its supply of the obesity drug Wegovy, the company reports on its website.

This means that doses of 0.25 mg, 0.5 mg and 1 mg are being replenished, while ongoing delays are still expected for doses of 1.7 mg and 2.4 mg for the rest of the year.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.